bioAffinity Technologies, Inc. – NASDAQ:BIAF

Add to watchlist

$0.262

-0.62

-70.56%

Market open

Closed in about 3 hours

-65.23%

month

-65.23%

quarter

-45.40%

year

Market Cap	14.33M
Enterprise value	N/A

P/E	-0.38
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	741.16
Price/Book	0.40
PEG ratio	0.01
EPS	-0.91

Revenue	4.93M
EBITDA	-7.94M
Income	-8.36M
Revenue Q/Q	261180.23%
Revenue Y/Y	86182.87%

Profit margin	-159014.32%
Oper. margin	-88757.91%
Gross margin	70.98%
EBIT margin	-88757.91%
EBITDA margin	-160.92%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

bioAffinity Technologies, Inc. (NASDAQ:BIAF): Profit margin
Jun 2023	19.73K	-1.74M	-8816.36%
Sep 2023	298.48K	-2.29M	-767.51%
Dec 2023	2.21M	-2.37M	-107.22%
Mar 2024	2.40M	-1.96M	-81.53%

bioAffinity Technologies, Inc. (NASDAQ:BIAF): Debt to assets
Jun 2023	8873499	775.15K	8.74%
Sep 2023	10189464	3.19M	31.36%
Dec 2023	8221552	3.36M	40.94%
Mar 2024	8049265	2.79M	34.69%

bioAffinity Technologies, Inc. (NASDAQ:BIAF): Cash Flow
Jun 2023	-1.35M	-3.86K	-126.09K
Sep 2023	-1.53M	-2.18M	-50.76K
Dec 2023	-1.61M	13.44K	-84.80K
Mar 2024	-2.34M	-41.38K	2.01M

bioAffinity Technologies alternative data

bioAffinity Technologies
Employees

bioAffinity Technologies, Inc. (NASDAQ:BIAF): Employee count
Aug 2023	14
Sep 2023	14
Oct 2023	14
Nov 2023	14
Dec 2023	14
Jan 2024	14
Feb 2024	14
Mar 2024	14
Apr 2024	14
May 2024	14
Jun 2024	14
Jul 2024	14

bioAffinity Technologies
Hedge Funds Holdings Q1 2023

0.05% -1.93%

of BIAF is owned by hedge funds

2 -3

hedge funds hold BIAF stock

2.44K -81.01K

shares is hold by hedge funds

BIAF hedge funds holdings changes

bioAffinity Technologies
Insider Trading

bioAffinity Technologies, Inc. (NASDAQ:BIAF): Insider trades (number of shares)
Period	Buy	Sel
Jul 2022	165628	0
Aug 2022	171624	0
Sep 2022	418973	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	8 Apr 2024	ZANNES MARIA officer: President & CEO officer: President & CEO	Common Stock	64,848	$1.16	$75,224
Option	8 Apr 2024	ZANNES MARIA officer: President & CEO officer: President & CEO	Stock Option (right to buy)	64,848	$1.16	$75,224
Option	4 Apr 2024	ZANNES TIMOTHY P officer: Secretary, EVP, Gen. Counsel officer: Secretary, EVP, Gen. C..	Common Stock	64,848	$1.16	$75,224
Option	4 Apr 2024	ZANNES TIMOTHY P officer: Secretary, EVP, Gen. Counsel officer: Secretary, EVP, Gen. C..	Stock Option (right to buy)	64,848	$1.16	$75,224
Option	3 Apr 2024	GIRGENTI STEVEN director director	Common Stock	64,848	$1.16	$75,224
Option	3 Apr 2024	GIRGENTI STEVEN director director	Stock Option (right to buy)	64,848	$1.16	$75,224
Option	26 Feb 2024	ANDERSON ROBERT A. director director	Common Stock	64,848	$1.16	$74,899
Option	26 Feb 2024	ANDERSON ROBERT A. director director	Stock Option (right to buy)	64,848	$1.12	$72,306
Purchase	6 Sep 2022	GIRGENTI STEVEN officer: Executive Chairman officer: Executive Chairman	Warrants (right to buy)	5,952	N/A	N/A
Purchase	6 Sep 2022	RUBIN GARY D director director	Warrants (right to buy)	408,125	N/A	N/A

BIAF insider trading transactions

bioAffinity Technologies
Latest News

Tuesday, 17 December 2024
08:00	Join bioAffinity Technologies' Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19	businesswire.com
Monday, 4 November 2024
08:00	bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development	businesswire.com
Monday, 21 October 2024
11:39	WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement	prnewswire.com
10:45	bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement	businesswire.com
Friday, 18 October 2024
14:57	WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement	prnewswire.com
12:45	bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement	businesswire.com
Wednesday, 9 October 2024
08:00	bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test	businesswire.com
Monday, 5 August 2024
14:00	WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million	prnewswire.com
13:17	bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million	businesswire.com
Friday, 2 August 2024
10:00	WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million	prnewswire.com
Friday, 12 July 2024
09:35	Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV	accesswire.com
Friday, 5 July 2024
09:00	BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV	accesswire.com
Wednesday, 12 June 2024
08:00	bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests	businesswire.com
Wednesday, 15 May 2024
09:15	bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes	businesswire.com

Frequently Asked Questions (FAQ)

What's the price of bioAffinity Technologies stock today?

One share of bioAffinity Technologies stock can currently be purchased for approximately $0.26.
When is bioAffinity Technologies's next earnings date?

Unfortunately, bioAffinity Technologies's (BIAF) next earnings date is currently unknown.
Does bioAffinity Technologies pay dividends?

No, bioAffinity Technologies does not pay dividends.
How much money does bioAffinity Technologies make?

bioAffinity Technologies has a market capitalization of 14.33M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 52627.44% to 2.53M US dollars.
What is bioAffinity Technologies's stock symbol?

bioAffinity Technologies, Inc. is traded on the NASDAQ under the ticker symbol "BIAF".
What is bioAffinity Technologies's primary industry?

Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
How do i buy shares of bioAffinity Technologies?

Shares of bioAffinity Technologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does bioAffinity Technologies have?

As Jul 2024, bioAffinity Technologies employs 14 workers.
When bioAffinity Technologies went public?

bioAffinity Technologies, Inc. is publicly traded company for more then 3 years since IPO on 1 Sep 2022.
What is bioAffinity Technologies's official website?

The official website for bioAffinity Technologies is bioaffinitytech.com.
Where are bioAffinity Technologies's headquarters?

bioAffinity Technologies is headquartered at 22211 West Interstate 10, San Antonio, TX.
How can i contact bioAffinity Technologies?

bioAffinity Technologies's mailing address is 22211 West Interstate 10, San Antonio, TX and company can be reached via phone at 210 698 5334.

bioAffinity Technologies, Inc.

bioaffinitytech.com

Exchange:

NASDAQ

Full time employees:

Industry:

Medical - Diagnostics & Research

Sector:

Healthcare

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

210 698 5334

22211 West Interstate 10
San Antonio, TX 78257

CIK: 0001712762
ISIN: US09076W1099
CUSIP: 09076W109